1. Pink Sheet

Accelerated Approval: US FDA Review Of Expedited Program Could Bring More Withdrawals

 
• By Sue Sutter

Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals leads to removal of indications for two PD-1/L-1 inhibitors, AstraZeneca’s Imfinzi and Bristol-Myers Squibb’s Opdivo, both of which had failed confirmatory trials.

Boat deck
Is the FDA's Oncology Center of Excellence trying to clear the deck of accelerated approval indications with failed confirmatory trials? • Source: Shutterstock

The recent withdrawal of accelerated approval indications for two cancer immunotherapies is part of a broader US Food and Drug Evaluation review of the expedited pathway and could portend more oncology drug and indication removals for failure to confirm clinical benefit.

On 22 February, AstraZeneca PLC announced the withdrawal of its PD-L1 inhibitor Imfinzi (durvalumab) for use in previously treated adults with locally advanced or metastatic bladder cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards